Core Viewpoint - INVO Fertility, Inc. has announced a strategic separation of its fertility and oncology operations to maximize shareholder value, returning to a focus on the fertility marketplace and the distribution of its FDA-cleared INVOcell device [1][4][5] Group 1: Company Name Change and Structure - The company has been renamed to "INVO Fertility, Inc." effective April 14, 2025, with a new Nasdaq ticker symbol "IVF" to be implemented soon [2] - The separation will allow INVO Fertility to concentrate on building, acquiring, and operating fertility clinics, as well as distributing the INVOcell device [3][4] Group 2: Business Focus and Operations - INVO Fertility will leverage its existing operations in Wisconsin, Alabama, and Georgia to expand its network of fertility centers across the U.S. [5] - The company currently operates two INVO Centers and one IVF clinic, focusing on assisted reproductive technology (ART) care [6] Group 3: NAYA Therapeutics - NAYA Therapeutics will operate as a private company focusing on the clinical development of bifunctional antibodies, with the company retaining a minority stake to benefit from potential value appreciation [4][7] - NAYA Therapeutics has a portfolio that includes several bifunctional antibodies targeting various cancers, with clinical trials expected to commence in the near future [7]
NAYA Biosciences Announces Strategic Decision to Separate Fertility and Oncology Businesses into Distinct Operations – Company Renamed "INVO Fertility, Inc."